Selected studies of allo-HCT in BPDCN
| Publication . | Study . | N . | Remission status at allo-HCT (n) . | Donor type (n) . | Regimen intensity (n) . | Outcomes . |
|---|---|---|---|---|---|---|
| Roos-Weil et al14 | EBMT | 34 | CR1 = 19 >CR1 = 15 | MSD = 11 MUD = 23 | MAC = 25 RIC/NMA = 9 | 3-y OS: 41% 3-y NRM: 30% 3-y relapse: 32% |
| Kharfan-Dabaja et al12 | North America | 37 | CR1 = 28 >CR1 = 9 | MSD=16 MUD = 12 Other: 9∗ | MAC = 20 RIC/NMA = 17 | 3-y OS: 58% 1-y NRM: 25% 3-y relapse: 10% |
| Bashir et al13 | MDACC | 17 | CR1 = 10 >CR1 = 7 | MSD = 5 MUD = 5 Other: 7† | MAC = 13 RIC/NMA = 4 | 5-y OS: 40% 1-y NRM: 29% 5-y relapse: 22% |
| Murthy et al (this study) | CIBMTR | 164 | CR = 121 >CR1 = 43 | MSD = 41 MUD = 65 Other = 58‡ | MAC = 84 RIC = 80 | 5-y OS: 51.2% 5-y NRM: 23.3% 5-y relapse: 32.2% |
| Publication . | Study . | N . | Remission status at allo-HCT (n) . | Donor type (n) . | Regimen intensity (n) . | Outcomes . |
|---|---|---|---|---|---|---|
| Roos-Weil et al14 | EBMT | 34 | CR1 = 19 >CR1 = 15 | MSD = 11 MUD = 23 | MAC = 25 RIC/NMA = 9 | 3-y OS: 41% 3-y NRM: 30% 3-y relapse: 32% |
| Kharfan-Dabaja et al12 | North America | 37 | CR1 = 28 >CR1 = 9 | MSD=16 MUD = 12 Other: 9∗ | MAC = 20 RIC/NMA = 17 | 3-y OS: 58% 1-y NRM: 25% 3-y relapse: 10% |
| Bashir et al13 | MDACC | 17 | CR1 = 10 >CR1 = 7 | MSD = 5 MUD = 5 Other: 7† | MAC = 13 RIC/NMA = 4 | 5-y OS: 40% 1-y NRM: 29% 5-y relapse: 22% |
| Murthy et al (this study) | CIBMTR | 164 | CR = 121 >CR1 = 43 | MSD = 41 MUD = 65 Other = 58‡ | MAC = 84 RIC = 80 | 5-y OS: 51.2% 5-y NRM: 23.3% 5-y relapse: 32.2% |
MDACC, MD Anderson Cancer Center; MSD, matched sibling donor; MUD, matched unrelated donor.
Umbilical cord blood = 4, haploidentical = 3, mismatch unrelated = 2.
Umbilical cord blood = 3, haploidentical = 4.
Umbilical cord blood = 11, haploidentical = 28, mismatch unrelated = 10, multidonor = 1, unknown = 8.